The Influence Of Superdisintegrants On Immediate Release - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

The Influence Of Superdisintegrants On Immediate Release

Pharmaceutical Technology Europe
Volume 23, Issue 6

John Fitzpatrick
When it comes to immediate‑release tablet formulations, the choice of disintegrant can have a significant effect on the rate and extent of drug dissolution. Once a tablet disintegrates, the characteristics of the API, either alone or assisted by other formulation ingredients, determine the dissolution rate and extent of the API. Thus, the choice of superdisintegrant is important, especially with poorly soluble APIs.

Not all superdisintegrants are the same

The three most common classes of superdisintegrants are: crospovidone, croscarmellose sodium and sodium starch glycolate. In general, all of these provide rapid disintegration at low use levels in both wet and dry granulations and direct compression tablet processes; however, the classes of disintegrants differ in chemistry and particle morphology. Crospovidone possesses unique pyrrolidone chemistry and a highly porous particle morphology that results in high surface area. The high surface area combined with unique chemistry results in high-interfacial activity that serves to enhance the dissolution of poorly soluble drugs in a way that is not possible with other disintegrant technologies. Indeed, studies have shown that tablets containing a poorly soluble API and crospovidone, Type B, have significantly faster dissolution rates compared with tablets formulated with other superdisintegrants (1).

It has been widely reported that more than 60% of drugs in development and over 40% of recently launched drugs have issues related to poor solubility, leading to long development times or cancellations. Before evaluating advanced techniques, such as amorphous solid dispersions, more traditional approaches such as the influence of superdisintegrants on dissolution are now being considered. The selection of a superdisintegrant and the use level plays a key role in determining the drug release of finished formulations

Choosing an optimal superdisintegrant

It is important to consider the impact of the superdisintegrant with respect to the performance of the final dosage form. As drug dissolution is essential for absorption by the body, formulators no longer select disintegrants based on the lowest disintegration time because it is important to also consider the effect of the superdsintegrant on dissolution. Additionally, the ionic nature of both the API and the superdisintegrants must also be considered. Anionic superdisintegrants, such as croscarmellose sodium and sodium starch glycolate, can interact with cationic APIs and retard dissolution. Thus, nonionic superdistegrants are preferred when working with cationic APIs. Formulators also consider the impact of the superdisintegrant on physical tablet characteristics, such as tablet breaking force and friability. In today’s high-speed tablet presses, superdisintegrants that provide tablets with high breaking force and low friability, while maintaining fast disintegration, are particularly important.

Oral disintegrating tablets (ODTs)

There are a growing number of oral disintegrating tablets (ODTs) and chewable tablets available on the market. These products have increased in popularity because consumers—old and young—find them convenient and easy to use. In addition, pharmaceutical companies have found an opportunity to extend product lifecycles or differentiate their products by offering these new dosage forms. To achieve rapid disintegration in the mouth in a direct compression ODT formulation, the selection of superdisintegrant and optimisation of use level is an important consideration. In a recent internal ISP survey of commercially marketed ODT products, it was found that more than 60% of the products surveyed used a superdisintegrant. The most common superdisintegrant listed in the ingredients was crospovidone.

New innovation

One recent innovation from ISP is the introduction of two new Grades of crospovidone that have lower specifications for peroxides compared with other commercially available crospovidone products. These low peroxide levels are achieved by manufacturing, drying, packaging and sealing the product under inert conditions to limit peroxide formation.

It is likely that the proliferation of blended/co-processed systems will continue, but the major innovations will be at the polymer chemistry level. With a better understanding of the physico-chemical properties achievable via advanced polymer science, improvements such as optimised particle morphology, cross-link density and purity will lead to new formulation and processing approaches. 


1. J. Balasubramaniam and T. Bee, Pharmaceutical Technology, Excipient suppl. s24–s14 (2009).

John Fitzpatrick is Global Director, Plasdone and Polyplasdone at ISP.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here